Zylox-Tonbridge Medical Technology Co., Ltd. executed an on-market repurchase of 59,000 H shares on 13 July 2026, paying a volume-weighted average price of HKD 19.19 per share within a daily trading range of HKD 18.94–19.50. The transaction totalled HKD 1.13 million.

Following the buyback, Zylox-Tonbridge’s issued share capital (excluding treasury shares) declined by 0.0178% to 323.66 million shares, while treasury shares rose to 12.69 million. The company’s overall share count, including treasury shares, remains at 336.35 million.

The purchase was made under the general mandate approved on 13 May 2026, which authorises repurchases of up to 32.72 million shares. To date, Zylox-Tonbridge has repurchased 3.54 million shares under the mandate, equating to 1.06% of the shares outstanding on the mandate date.

All regulatory requirements of the Hong Kong Stock Exchange Main Board Rules were observed. In line with listing regulations, the company is subject to a moratorium on issuing new shares or selling treasury shares until 12 August 2026.